| abstract |
1. The compound selected from Table 1, or its pharmaceutically acceptable salt: 2. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 13, 28, 29, 30, 31, 32, 33, 34, 40, 41, 43, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 77, 79, 81, 82, 84, 85, 87, 88, 90, 94, 95, 96, 97, 98, 99, 100 and 101.3. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 13, 29, 30, 33, 34, 41, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 75, 79, 81, 82, 85, 87, 88, 90, 94, 95, 97, 99 and 101.4. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 13, 28, 29, 30, 32, 33, 34, 40, 41, 43, 60, 61, 64, 69, 70, 75, 77, 79, 81, 82, 84, 85, 87, 88, 90, 94, 95, 96, 97, 98, 99, 100 and 101.5. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 13, 28, 29, 32, 34, 40, 41, 43, 60, 61, 77, 79, 81, 82, 84, 87 and 100.6. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 29, 34, 41, 77, 79, 81, 82, and 87.7. The compound according to claim 1, characterized in that it is selected from the group consisting of compounds numbered 34, 41, 77, 79, 81, 82 and 87.8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, base or adjuvant. The pharmaceutical composition of claim 1, further comprising at least one additional therapeutic agent. The pharmaceutical composition according to claim 9, characterized in that the additional therapeutic agent is selected from the group consisting of painkillers, non-steroidal anti-inflammatory drugs (NSAIDs), cannabinoid receptor agonists, opioid receptor agonists, anti-infective drugs, sodium channel blockers, � |